Agios Pharmaceuticals (AGIO) vs Palvella Therapeutics (PVLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Agios Pharmaceuticals (AGIO) over the past year, gaining 75.5% versus a loss of 25.1%. Over five years, AGIO leads with a -31.0% price change compared with -63.6% for PVLA. Palvella Therapeutics is the larger company by market cap ($1.92 billion vs $1.91 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGIO | PVLA |
|---|---|---|
| Share price | $31.98 | $133.30 |
| Market cap | $1.91B | $1.92B |
| 1-day change | +0.20% | +1.49% |
| YTD return | +17.27% | +25.48% |
| 1-year return | -25.07% | +75.47% |
| 5-year return | -31.03% | -63.60% |
| EPS (TTM) | $-7.01 | $-4.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $54.03M | — |
| Revenue growth (YoY) | +48.03% | — |
| Net income (latest FY) | $-412.78M | $-41.72M |
| Gross margin | 88.26% | — |
| Operating margin | -873.87% | — |
| Net margin | -764.01% | — |
| 52-week high | $46.00 | $161.38 |
| 52-week low | $22.24 | $65.93 |
| Distance from 52-week high | -30.47% | -17.40% |
| Analyst consensus | buy | none |
| Avg. price target upside | +43.82% | +72.95% |
| Average volume | 1.08M | 211.36K |
| Shares outstanding | 59.70M | 14.41M |
| Employees | 539 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed AGIO by 100.5 percentage points over the past year.
About Agios Pharmaceuticals
AGIO stock →Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
AGIO vs PVLA FAQ
Which is bigger, Agios Pharmaceuticals or Palvella Therapeutics?
Palvella Therapeutics (PVLA) is larger, with a market capitalization of $1.92B compared with $1.91B for Agios Pharmaceuticals (AGIO).
Which stock has performed better over the past year, AGIO or PVLA?
PVLA returned +75.47% over the past 12 months, compared with -25.07% for AGIO (price return, excluding dividends). Past performance does not predict future results.
Are Agios Pharmaceuticals and Palvella Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.